Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Emil Kakkis Sells 54,404 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil Kakkis sold 54,404 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. This represents a 7.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ultragenyx Pharmaceutical Stock Down 4.1%

Shares of RARE opened at $22.07 on Wednesday. The stock has a fifty day simple moving average of $23.82 and a two-hundred day simple moving average of $29.24. The company has a market capitalization of $2.13 billion, a PE ratio of -3.78 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same quarter in the previous year, the business posted ($1.39) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Management presentation transcript from TD Cowen’s 46th Annual Health Care Conference is available; this is informational for modeling product timelines and pipeline commentary but contains no new regulatory decisions. TD Cowen Presentation Transcript
• Negative Sentiment: Large, concentrated insider selling by multiple senior executives (CEO Emil Kakkis sold 54,404 shares; several EVPs, the CFO and CAO also sold material blocks) — these trades reduced several insiders’ holdings by ~3–10% and totaled well over $1M for the CEO alone. Such coordinated/large insider liquidity can signal personal cash needs or tax planning, but markets often read it as a negative signal for near-term sentiment. SEC filing (CEO sale) here: Insider Sale SEC Filing
• Negative Sentiment: Multiple law firms have announced or are soliciting lead plaintiffs for a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering Aug 3, 2023–Dec 26, 2025; several firms set April 6 lead‑plaintiff deadlines. The proliferation of notices and a filed class action increases legal and financial uncertainty and is likely exerting downward pressure on the stock. Example notice: Kessler Topaz Class Action Notice

Analyst Upgrades and Downgrades

RARE has been the subject of several analyst reports. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Truist Financial cut their price objective on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Jefferies Financial Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Finally, Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $68.29.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after acquiring an additional 29,984 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 6.0% during the second quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after purchasing an additional 1,698 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of Ultragenyx Pharmaceutical by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after purchasing an additional 404 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Ultragenyx Pharmaceutical by 9.7% in the second quarter. Amalgamated Bank now owns 6,757 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 598 shares during the period. Finally, EFG Asset Management North America Corp. grew its holdings in shares of Ultragenyx Pharmaceutical by 10.5% in the second quarter. EFG Asset Management North America Corp. now owns 135,850 shares of the biopharmaceutical company’s stock valued at $4,939,000 after purchasing an additional 12,908 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.